[ad_1]
The Biden administration on Friday announced an agreement to purchase 100,000 doses of Eli Lilly’s monoclonal antibody cocktail, recently cleared by the Food and Drug Administration (FDA).
The move will increase the available supply of one of the few proven treatments for people with COVID-19. Antibody-based drugs are allowed in patients who are at high risk of becoming seriously ill but who have not yet been hospitalized.
Under the deal, the federal government will pay $ 210 million for the initial purchase of up to 100,000 courses of treatment of the drug, which is a combination of the drug bamlanivimab, which was cleared last November for patients at high risk COVID-19, with a second drug known as etesevimab.
The suit has received emergency use authorization earlier this month, after data showed it reduced the risk of hospitalization and death by 70%.
The deal includes the flexibility to buy up to a total of 1.2 million doses through November, but that will likely depend on how the pandemic progresses in the coming months.
The government has already pledged to purchase a total of 1,450,000 doses of bamlanivimab alone, which includes over a million doses that have been delivered and an agreement to distribute 450,000 additional doses by the end of the month. Of March.
The government has said it will provide neutralizing antibodies at no cost to patients, although healthcare facilities may charge a fee for administering the product.
To receive therapeutic antibody treatment, patients should contact their health care providers.
Another antibody treatment made by Regeneron is also cleared by the FDA. Regeneron supplies the federal government with up to 1.5 million doses.
But despite their effectiveness and federal efforts to encourage use, antibody therapy has seen lackluster demand.
The supply was limited at first, and getting the drug to the patients is a complex undertaking. Since these are drugs for infusion, antibodies should be administered in the appropriate setting. The window for administering drugs is small and patients need a quick diagnosis.
Getting patients to an infusion center or hospital is difficult, especially as the out-of-control pandemic puts considerable strain on hospitals and health workers. Experts have called for a better system to make sure drugs can reach patients who need them most.
Monoclonal antibody treatments received a publicity boost last fall when they were given to a former President Trump
Donald Trump Donald Trump Jr. calls Bruce Springsteen the ‘liberal privilege’ of charges dropped Schiff sees challenges for intel committee, community in Trump’s shadow McConnell says he would support Trump as GOP 2024 PLUS candidate when he got infected last fall.
The treatments were also given to high-profile Republicans and Trump allies, such as his personal lawyer. Rudy Giuliani
Rudy Giuliani MyPillow CEO says boycotts cost him Mr. Dominion targets MyPillow’s Mike Lindell with .3B libel lawsuit Trump’s legal troubles may not be over despite Senate acquittal READ MORE, former governor of New Jersey. Chris Christie
Chris ChristieCancun fallout threatens to inflict lasting damage on Cruz On The Trail: Political Perils of Snowmageddon Assistant Ex-Christie Erased by Supreme Court in ‘Bridgegate’ Scandal Running for Local Office MORE and former secretary of housing and urban development Ben carson
Ben Carson Ben Carson Launches Conservative Think Tank Trump’s ‘1776 Report’, released on MLK Day, receives strong backlash Biden on opportunity to win over conservative Christians MORE.
[ad_2]
Source link